Abstract
Atopic dermatitis (AD) is characterized by epidermal dysfunction and interleukin (IL)-4/IL-13-predominant inflammation. Dupilumab, a monoclonal antibody that targets IL-4Rα, has demonstrated clinical efficacy/safety in AD. The skin barrier proteomic changes in AD patients with dupilumab treatment are not established.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have